Business
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeuti
About this update from Novartis Ag
[{"type":"image","alt":"Excellergy, Inc.","displaySize":"","headline":null,"caption":"Excellergy, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/37e9d860c455f82c5082caf9fdf58ee1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YbBdgHJHZ2TcsKBGelIEEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Ng--/https://media.zenfs.com/en/globenewswire.com/37e9d860c455f82c5082caf9fdf58ee1","width":300,"height":133}},"lazy":false},{"type":"text","content":"– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion –","length":232,"tagName":"p"},{"type":"text","content":"– Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development –","length":134,"tagName":"p"},{"type":"text","content":"PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeutics, today announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis.","length":407,"tagName":"p"},{"type":"text","content":"Exl-111 is a trifunctional ECRI designed to disarm allergic effector cells at the source of activation by targeting the IgE axis. Exl-111 is currently being evaluated in the Phase 1 DISARM trial, a randomized, double-blind, placebo-controlled, single and multiple ascending dose trial, with the first subjects dosed in early February 2026.","length":339,"tagName":"p"},{"type":"text","content":""This acquisition validates the transformative potential of our ECRIs and the hard work of the entire Excellergy team. Novartis brings world-class global development capabilities and a proven track record of bringing novel medicines to patients. Together, we will be ideally positioned to realize the full potential of Exl-111 and the broader ECRI pipeline for the millions of patients living with severe, debilitating allergic diseases", said Todd Zavodnick, Chief Executive Officer of Excellergy.","length"...